A Phase 4 interventional study of rosuvastatin in Metabolic Syndrome, sponsored by AstraZeneca. Completed at 6 sites in Turkey. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2011-08-31.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Metabolic Syndrome with a site in Turkey — 14 open to participants now, 16 under way, none of them phase 3. Metabolic Syndrome · Turkey.
Among the 54 studies in Metabolic Syndrome with a site in Turkey, this one is the 8th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2008, is one of 4 in phase 4, and was the 4th registered.
2,118 studies on the registry are indexed under Metabolic Syndrome; 348 are open to participants now.
Browse Metabolic Syndrome studies →14 of the 54 studies in Metabolic Syndrome with a site in Turkey are open now. Recruiting first, the newest first:
Karamanoğlu Mehmetbey University · Sites in Turkey
Ages 18+
Sisli Hamidiye Etfal Training and Research Hospital · Sites in Turkey
Ages 40–75
Abant Izzet Baysal University · Sites in Turkey
Ages 18–65
Yaşar Bayındır, MD · Sites in Turkey
Ages 18+ · Healthy volunteers
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–50 · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 232 Metabolic Syndrome studies recruiting now, 68 (29%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is above the median of 60 across 1,573 interventional studies indexed under Metabolic Syndrome.
Median enrollment 76 across the 20 interventional studies, 102 across the 34 observational. Of the 33 that completed or were terminated, 4 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 54 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 9 studies filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
6 of the studies in Metabolic Syndrome with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07890155Sisli Hamidiye Etfal Training and Research HospitalEffect of Resistance Exercises on Serum IGF-1 Levels in Knee Osteoarthritis | 2026-12-01 |
| NCT07643376Toros UniversityEvaluation of Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms After Bariatric Surgery in Body Weight Management | 2027-01-01 |
| NCT07942415Recep Tayyip Erdogan University Training and Research HospitalStress Levels Periodontitis and Metabolic Syndrome | 2027-03-15 |
| NCT07731360Kayseri City HospitalNon-Invasive Diagnostic Panel for MASLD in Children With Obesity | 2027-04-01 |
| NCT07731373Kayseri City HospitalBiomarker Panel for PCOS-Associated Liver Steatosis in Adolescent Girls (COMPASS-pedPCOS) | 2027-04-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 54 studies in Metabolic Syndrome with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective is to evaluate the efficacy of rosuvastatin therapy on plasma lipid profile (Low Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), total cholesterol, triglyceride) in patients with metabolic syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
Drug: rosuvastatin
medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
Also known as: CRESTOR
Basal HDL-cholesterol Level
HDL-cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)
Time frame: Baseline
HDL-cholesterol Level After 3 Months of Rosuvastatin Treatment
HDL- cholesterol levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Basal LDL-cholesterol Level
LDL-cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)
Time frame: Baseline
LDL-cholesterol Level After 3 Months of Rosuvastatin Treatment
LDL- cholesterol levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Basal Total Cholesterol Level
Baseline
Time frame: Total cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)
Total Cholesterol Level After 3 Months of Rosuvastatin Treatment
Total cholesterol after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Basal Triglyceride Level
Triglyceride levels before (mean of visit 1 - screening and Visit 2 - enrollment)
Time frame: Baseline
Triglyceride Level After 3 Months of Rosuvastatin Treatment
Triglycerides after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Number of Patients Who Reached Target Level of LDL-cholesterol After 3 Months of Rosuvastatin Treatment
Number of patients who reached target level of LDL-cholesterol after 3 months of rosuvastatin treatment. Target level: LDL-cholesterol: \<100 mg/dL; HDL-cholesterol: For males \>40 mg/dL, for females \>50 mg/dL; non-HDL-cholesterol: \<130 mg/dL
Time frame: 3 months (from enrollment to last visit)
Number of Patients Who Reached Target Level of HDL-cholesterol After 3 Months of Rosuvastatin Treatment
Number of patients who reached target level of HDL-cholesterol after 3 months of rosuvastatin treatment
Time frame: 3 months (from enrollment to last visit)
Number of Patients Who Reached Target Level of Non-HDL-cholesterol After 3 Months of Rosuvastatin Treatment
Number of patients who reached target level of non-HDL-cholesterol after 3 months of rosuvastatin treatment
Time frame: 3 months (from enrollment to last visit)
Basal Interleukin 1 (IL-1) Level
IL-1 levels before (Visit 2-enrollment)
Time frame: Baseline
Interleukin 1 (IL-1) Level After 3 Months of Rosuvastatin Treatment
IL-1 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Basal Interleukin 6 (IL-6) Level
IL-6 levels before (Visit 2-enrollment)
Time frame: Baseline
Interleukin 6 (IL-6) Level After 3 Months of Rosuvastatin Treatment
IL-6 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Basal Interleukin 8 (IL-8) Level
IL-8 levels before (Visit 2-enrollment)
Time frame: Baseline
Interleukin 8 (IL-8) Level After 3 Months of Rosuvastatin Treatment
IL-8 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Basal Interleukin 10 (IL-10) Level
IL-10 levels before (Visit 2-enrollment)
Time frame: Baseline
Interleukin 10 (IL-10) Level After 3 Months of Rosuvastatin Treatment
IL-10 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Basal Tumor Necrosis Factor (TNF) Level
TNF levels before (Visit 2-enrollment)
Time frame: Baseline
Tumor Necrosis Factor (TNF) Level After 3 Months of Rosuvastatin Treatment
TNF levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Basal High Sensitivity C-reactive Protein (Hs-CRP) Level
hs-CRP levels before (Visit 2-enrollment)
Time frame: Baseline
High Sensitivity C-reactive Protein (Hs-CRP) Level After 3 Months of Rosuvastatin Treatment
hs-CRP levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Basal LDL-3 Level
LDL subfractions are light (LDL1 and 2), intermediate (LDL3) and small dense LDL (LDL 4, 5, 6 and 7). Small dense LDL (sdLDL)-cholesterol that expresses greater atherogenicity than large buoyant LDL. Large LDL particles are the least likely to cause plaque formation, because LDL particles have to be approximately 25 nm in diameter or smaller to penetrate the artery walls. High sdLDL and decreased large HDL fraction are more common in patients with coronary heart disease than in controls
Time frame: Baseline
LDL-3 Level After 3 Months of Rosuvastatin Treatment
LDL-3 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Basal LDL-4 Level
LDL-4 levels before (Visit 2-enrollment)
Time frame: Baseline
LDL-4 Level After 3 Months of Rosuvastatin Treatment
LDL-4 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Basal LDL-5 Level
LDL-5 levels before (Visit 2-enrollment)
Time frame: Baseline
LDL-5 Level After 3 Months of Rosuvastatin Treatment
LDL-5 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Basal LDL-6 Level
LDL-6 levels before (Visit 2-enrollment)
Time frame: Baseline
LDL-6 Level After 3 Months of Rosuvastatin Treatment
LDL-6 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Basal LDL-7 Level
LDL-7 levels before (Visit 2-enrollment)
Time frame: Baseline
LDL-7 Level After 3 Months of Rosuvastatin Treatment
LDL-7 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Basal Large HDL Subfraction Level
Large HDL subfraction levels before (Visit 2-enrollment)
Time frame: Baseline
Large HDL Subfraction Level After 3 Months of Rosuvastatin Treatment
Large HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Basal Intermediate HDL Subfraction Level
Intermediate HDL subfraction levels before (Visit 2-enrollment)
Time frame: Baseline
Intermediate HDL Subfraction Level After 3 Months of Rosuvastatin Treatment
Intermediate HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Basal Small HDL Subfraction Level
Small HDL subfraction levels before (Visit 2-enrollment)
Time frame: Baseline
Small HDL Subfraction Level After 3 Months of Rosuvastatin Treatment
Small HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
Time frame: 3 months (from enrollment to last visit)
Number of Patients With Adverse Events
Number of patients with any adverse events in 3 months of rosuvastatin treatment
Time frame: 3 months (from enrollment to last visit)
| Milestone | Crestor |
|---|---|
| Started | 97 |
| Completed | 74 |
| Not completed | 23 |
| Withdrew: Adverse event | 9 |
| Withdrew: Withdrawal by subject | 9 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Protocol violation | 1 |
HDL-cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)
| mg/dL | Crestor |
|---|---|
| Basal HDL-cholesterol Level | 39.5 ± 6.5 |
HDL- cholesterol levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| mg/dL | Crestor |
|---|---|
| HDL-cholesterol Level After 3 Months of Rosuvastatin Treatment | 43.4 ± 9.8 |
LDL-cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)
| mg/dL | Crestor |
|---|---|
| Basal LDL-cholesterol Level | 165.5 ± 32.0 |
LDL- cholesterol levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| mg/dL | Crestor |
|---|---|
| LDL-cholesterol Level After 3 Months of Rosuvastatin Treatment | 98.3 ± 44.8 |
Baseline
| mg/dL | Crestor |
|---|---|
| Basal Total Cholesterol Level | 236.5 ± 38.2 |
Total cholesterol after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| mg/dL | Crestor |
|---|---|
| Total Cholesterol Level After 3 Months of Rosuvastatin Treatment | 166.2 ± 47.7 |
Triglyceride levels before (mean of visit 1 - screening and Visit 2 - enrollment)
| mg/dL | Crestor |
|---|---|
| Basal Triglyceride Level | 195.1 ± 65.3 |
Triglycerides after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| mg/dL | Crestor |
|---|---|
| Triglyceride Level After 3 Months of Rosuvastatin Treatment | 153.1 ± 76.8 |
Number of patients who reached target level of LDL-cholesterol after 3 months of rosuvastatin treatment. Target level: LDL-cholesterol: \<100 mg/dL; HDL-cholesterol: For males \>40 mg/dL, for females \>50 mg/dL; non-HDL-cholesterol: \<130 mg/dL
| Participants | Crestor |
|---|---|
| Number of Patients Who Reached Target Level of LDL-cholesterol After 3 Months of Rosuvastatin Treatment | 48 |
Number of patients who reached target level of HDL-cholesterol after 3 months of rosuvastatin treatment
| Participants | Crestor |
|---|---|
| Number of Patients Who Reached Target Level of HDL-cholesterol After 3 Months of Rosuvastatin Treatment | 39 |
Number of patients who reached target level of non-HDL-cholesterol after 3 months of rosuvastatin treatment
| Participants | Crestor |
|---|---|
| Number of Patients Who Reached Target Level of Non-HDL-cholesterol After 3 Months of Rosuvastatin Treatment | 51 |
IL-1 levels before (Visit 2-enrollment)
| pg/mL | Crestor |
|---|---|
| Basal Interleukin 1 (IL-1) Level | 4.1 ± 2.3 |
IL-1 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| pg/mL | Crestor |
|---|---|
| Interleukin 1 (IL-1) Level After 3 Months of Rosuvastatin Treatment | 4.1 ± 2.2 |
IL-6 levels before (Visit 2-enrollment)
| pg/mL | Crestor |
|---|---|
| Basal Interleukin 6 (IL-6) Level | 2.6 ± 2.1 |
IL-6 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| pg/mL | Crestor |
|---|---|
| Interleukin 6 (IL-6) Level After 3 Months of Rosuvastatin Treatment | 2.8 ± 2.8 |
IL-8 levels before (Visit 2-enrollment)
| pg/mL | Crestor |
|---|---|
| Basal Interleukin 8 (IL-8) Level | 10.7 ± 5.1 |
IL-8 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| pg/mL | Crestor |
|---|---|
| Interleukin 8 (IL-8) Level After 3 Months of Rosuvastatin Treatment | 12.7 ± 13.3 |
IL-10 levels before (Visit 2-enrollment)
| pg/mL | Crestor |
|---|---|
| Basal Interleukin 10 (IL-10) Level | 4.2 ± 2.1 |
IL-10 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| pg/mL | Crestor |
|---|---|
| Interleukin 10 (IL-10) Level After 3 Months of Rosuvastatin Treatment | 4.8 ± 3.9 |
TNF levels before (Visit 2-enrollment)
| pg/mL | Crestor |
|---|---|
| Basal Tumor Necrosis Factor (TNF) Level | 10.8 ± 5.3 |
TNF levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| pg/mL | Crestor |
|---|---|
| Tumor Necrosis Factor (TNF) Level After 3 Months of Rosuvastatin Treatment | 12.9 ± 9.2 |
hs-CRP levels before (Visit 2-enrollment)
| mg/mL | Crestor |
|---|---|
| Basal High Sensitivity C-reactive Protein (Hs-CRP) Level | 8.2 ± 7.3 |
hs-CRP levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| mg/mL | Crestor |
|---|---|
| High Sensitivity C-reactive Protein (Hs-CRP) Level After 3 Months of Rosuvastatin Treatment | 6.7 ± 5.6 |
LDL subfractions are light (LDL1 and 2), intermediate (LDL3) and small dense LDL (LDL 4, 5, 6 and 7). Small dense LDL (sdLDL)-cholesterol that expresses greater atherogenicity than large buoyant LDL. Large LDL particles are the least likely to cause plaque formation, because LDL particles have to be approximately 25 nm in diameter or smaller to penetrate the artery walls. High sdLDL and decreased large HDL fraction are more common in patients with coronary heart disease than in controls
| mg/mL | Crestor |
|---|---|
| Basal LDL-3 Level | 15.5 ± 9.5 |
LDL-3 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| mg/mL | Crestor |
|---|---|
| LDL-3 Level After 3 Months of Rosuvastatin Treatment | 8.8 ± 7.9 |
LDL-4 levels before (Visit 2-enrollment)
| mg/mL | Crestor |
|---|---|
| Basal LDL-4 Level | 7.9 ± 9.6 |
LDL-4 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| mg/mL | Crestor |
|---|---|
| LDL-4 Level After 3 Months of Rosuvastatin Treatment | 3.5 ± 4.8 |
LDL-5 levels before (Visit 2-enrollment)
| mg/mL | Crestor |
|---|---|
| Basal LDL-5 Level | 2.7 ± 7.1 |
LDL-5 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| mg/mL | Crestor |
|---|---|
| LDL-5 Level After 3 Months of Rosuvastatin Treatment | 1.3 ± 3.5 |
LDL-6 levels before (Visit 2-enrollment)
| mg/mL | Crestor |
|---|---|
| Basal LDL-6 Level | 0.5 ± 2.6 |
LDL-6 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| mg/mL | Crestor |
|---|---|
| LDL-6 Level After 3 Months of Rosuvastatin Treatment | 0.3 ± 1.5 |
LDL-7 levels before (Visit 2-enrollment)
| mg/mL | Crestor |
|---|---|
| Basal LDL-7 Level | 0.5 ± 3.0 |
LDL-7 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| mg/mL | Crestor |
|---|---|
| LDL-7 Level After 3 Months of Rosuvastatin Treatment | 0.8 ± 5.3 |
Large HDL subfraction levels before (Visit 2-enrollment)
| mg/mL | Crestor |
|---|---|
| Basal Large HDL Subfraction Level | 15.0 ± 6.4 |
Large HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| mg/mL | Crestor |
|---|---|
| Large HDL Subfraction Level After 3 Months of Rosuvastatin Treatment | 17.6 ± 7.6 |
Intermediate HDL subfraction levels before (Visit 2-enrollment)
| mg/mL | Crestor |
|---|---|
| Basal Intermediate HDL Subfraction Level | 18.9 ± 5.7 |
Intermediate HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| mg/mL | Crestor |
|---|---|
| Intermediate HDL Subfraction Level After 3 Months of Rosuvastatin Treatment | 19.9 ± 6.1 |
Small HDL subfraction levels before (Visit 2-enrollment)
| mg/mL | Crestor |
|---|---|
| Basal Small HDL Subfraction Level | 6.2 ± 4.2 |
Small HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)
| mg/mL | Crestor |
|---|---|
| Small HDL Subfraction Level After 3 Months of Rosuvastatin Treatment | 6.6 ± 4.6 |
Number of patients with any adverse events in 3 months of rosuvastatin treatment
| Participants | Crestor |
|---|---|
| Number of Patients With Adverse Events | 24 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Crestor | — | 0/97 (0%) | 29/97 (29.9%) |
| Event | Crestor |
|---|---|
| Pruritus-Allergy-RashSkin and subcutaneous tissue disorders | 5/97 |
| HeadacheSkin and subcutaneous tissue disorders | 4/97 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/97 |
| CK IncreasedInvestigations | 2/97 |
| DysuriaInfections and infestations | 2/97 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/97 |
| Liver Function Tests AbnormalInfections and infestations | 2/97 |
| NauseaGastrointestinal disorders | 1/97 |
| AllergyGastrointestinal disorders | 1/97 |
| DermatoidSkin and subcutaneous tissue disorders | 1/97 |
| Age Continuous(Years) | Crestor |
|---|---|
| Mean | 50.9 ± 9.5 |
| Sex: Female, Male(Participants) | Crestor |
|---|---|
| Female | 57 |
| Male | 40 |
The record gives a start of Dec 2008, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin